Clinical trials: Ductal Carcinoma In Situ, DCIS
Breast Cancer
Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery
This is a Phase 1, open-label, dose escalation study in women with primary, non-recurrent breast cancer undergoing surgery. AVB-620 will be administered prior to surgery.
- Trial name
- NCT02391194
- Testing
- AVB-620
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Avelas Biosciences, Inc.
Breast Carcinoma, Breast Ductal Carcinoma In Situ
Effect of PACK Health Support Program on Patient Reported Outcomes in Patients With Breast Cancer
This trial studies the effect of an electronic health (eHealth) support program called PACK Health on patient reported health outcomes in patients with breast cancer.
- Conditions
- Breast Carcinoma, Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Recurrent Breast Carcinoma
- Trial name
- NCT04022772
- Testing
- Best Practice, Medical Chart Review, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 287 people
- Sponsor
- M.D. Anderson Cancer Center
Invasive Breast Cancer, Ductal Carcinoma in Situ of the Breast
Axillary Reverse Mapping (ARM) Technique
The purpose of this pilot study is to compare a new surgical technique (axillary reverse mapping) to standard axillary surgery in patients diagnosed with invasive or in situ breast cancer.
- Trial name
- ARM (NCT03109522)
- Testing
- axillary reverse mapping (ARM), Standard axillary surgery (SLNB or ALND)
- Where
- 2 sites in Canada
- Volunteers
- 130 people
- Sponsor
- McMaster University
Atypical Ductal Breast Hyperplasia, Lobular Carcinoma in Situ (LCIS)
Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial
Atypical ductal hyperplasia (ADH) and atypical lobular hyperplasia (ALH) increases breast cancer risk. In post menopausal women, SERMS are standard chemopreventive agents.
- Conditions
- Atypical Ductal Breast Hyperplasia, Lobular Carcinoma in Situ (LCIS), Atypical Lobular Hyperplasia (ALH) of Breast
- Trial name
- NCT01372644
- Testing
- SOM 230 / Pasireotide
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
DCIS
Management of Low-risk (Grade I and II) DCIS
A substantial number of DCIS lesions will never form a health hazard, particularly if it concerns slow-growing low-risk DCIS (grade I and II).
- Trial name
- LORD (NCT02492607)
- Testing
- Standard treatment, digital mammography, radiotherapy
- Where
- 60 sites in Netherlands
- Volunteers
- 2,500 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer, Precancerous Condition
Broccoli Sprout Extract in Treating Women Who Have Had a Mammogram and Breast Biopsy
RATIONALE: Broccoli sprout extract supplements may slow the growth of tumor cells or abnormal cells and may be an effective treatment for ductal carcinoma in situ and/or atypical ductal hyperplasia.
- Trial name
- NCT00843167
- Testing
- broccoli sprout extract
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- OHSU Knight Cancer Institute
Breast Ductal Carcinoma In Situ
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
This phase Ib trial studies the side effects and best dose of a vaccine called H2NVAC before surgery in treating patients with HER2 expressing ductal carcinoma in situ.
- Trial name
- NCT04144023
- Testing
- Granulocyte-Macrophage Colony-Stimulating Factor, Multi-epitope HER2 Peptide Vaccine H2NVAC, Therapeutic Conventional Surgery
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- Mayo Clinic
Breast Cancer, Ductal Carcinoma In Situ
Breast Tumour Size Measurement by Field Cycling Imaging
The goal of this study is to test if a new type of MRI scanner, called Field-Cycling Imaging (FCI), can accurately estimate tumour size in patients with a type of breast cancer called ductal carcinoma in situ (DCIS).
- Trial name
- BREVIA (NCT07492043)
- Testing
- Field-Cycling Imaging research scan, 3T MRI research scan
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- University of Aberdeen
Ductal Breast Carcinoma in Situ
Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma
The purpose of this pilot study is to compare by pathological findings surgical excision versus neoadjuvant radiotherapy followed by delayed surgical excision of ductal carcinoma in situ (DCIS)
- Trial name
- NORDIS (NCT03909282)
- Testing
- Lumpectomy, Partial breast irradiation prior to surgery
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Stanford University
Breast Cancer, Ductal Carcinoma in Situ
Intraoperative Gamma Camera for Breast Cancer Surgery
Aim: This study aims at evaluating the performances of an intraoperative gamma camera (field of view 10X10 cm), named CarolIReS, to detect axillary drainage and to assess the removal of sentinel lymph nodes (SLN) in breast…
- Trial name
- NCT00757302
- Testing
- SLN procedure (CarolIReS camera)
- Where
- France
- Volunteers
- 110 people
- Sponsor
- University Hospital, Strasbourg, France
Breast Cancer, Ductal Carcinoma in Situ
Intraoperative Radiation Therapy (IORT) in DCIS
The goal of this study is to examine the role of Intraoperative Radiotherapy (IORT) in Ductal Carcinoma In-Situ (DCIS) and to improve the understanding of the clinical, radiographic, and patient-related impact of adopting IORT.
- Trial name
- NCT03216421
- Testing
- Quality of Life Questionnaires
- Where
- United States
- Volunteers
- 265 people
- Sponsor
- Columbia University
Breast Cancer, Stage 0
MRI Characterization of Mammographically Detected DCIS
This is a single institution, prospective observational clinical trial for women with mammographically identified calcifications that may represent ductal carcinoma in situ (DCIS).
- Trial name
- NCT03495011
- Testing
- Breast MRI, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- University of Washington
Breast Ductal Carcinoma in Situ
Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in Situ
Although the results obtained from ECOG E5194 cohort 1 (criteria: mammographically detected low- or intermediate-grade DCIS, measuring less than 2.5 cm with margins ≥ 3 mm) and RTOG 9804 trial (the same enrolled…
- Trial name
- NCT04046159
- Testing
- Low-dose tamoxifen, Whole breast radiotherapy
- Where
- Taiwan
- Volunteers
- 810 people
- Sponsor
- National Taiwan University Hospital
Carcinoma in Situ
Role of MRI Breast in Detection of Ductal Carcinoma in Situ
"This study investigates the role of Magnetic Resonance Imaging (MRI) in detecting Ductal Carcinoma in situ (DCIS) in high-risk breast cancer patients.
- Trial name
- NCT06744140
- Testing
- Magnetic Resonance Imaging (MRI)
- Where
- Pakistan
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Superior University
Ductal Breast Carcinoma in Situ, Invasive Breast Cancer
Hypofractionated Radiation Therapy vs Standard Treatment in Breast Cancer.
An explanatory study comparing complementary treatment to breast conservative surgery with radiation therapy DCIS, T1-T2 N0 M0 (AJCC v8) 1 week schedule vs 3.1 weeks standard schedule, in order to determine the equivalence of…
- Conditions
- Ductal Breast Carcinoma in Situ, Invasive Breast Cancer, Early-stage Breast Cancer, Stage 0 Breast Cancer
- Trial name
- NCT05318274
- Testing
- Hypofractionated radiotherapy
- Where
- Mexico
- Volunteers
- 72 people
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Breast Cancer
Sulindac in Preventing Breast Cancer in Women at High Risk for Breast Cancer
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of sulindac may prevent breast cancer.
- Trial name
- NCT00245024
- Testing
- sulindac, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8
Prospective Registry Trial for Single Port Robot-assisted Nipple Sparing Mastectomy (SPrNSM)
This is a prospective registry trial to determine the outcomes of single port robot-assisted nipple sparing mastectomy (SPrNSM) utilitzing the SP da Vinci surgical system.
- Conditions
- Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- SPrNSM (NCT04866992)
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Breast Cancer
Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of simvastatin and anastrozole may stop cancer from forming, growing, or coming back in patients with invasive…
- Trial name
- NCT00354640
- Testing
- anastrozole, simvastatin, pharmacological study
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer, Ductal Carcinoma In Situ
Hong Kong Breast Cancer Study
Introduction: With population ageing and increasing Westernization breast cancer continues to be important health conditions among women in Hong Kong.
- Trial name
- NCT02889458
- Testing
- Not Provided
- Where
- 21 sites in Hong Kong
- Volunteers
- 7,000 people
- Sponsor
- The University of Hong Kong
Invasive Ductal Carcinoma, Ductal Carcinoma in Situ
Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®
The purpose of this trial is to assess the safety and efficacy of the Xoft Axxent eBx System when used for single-fraction IORT in early stage breast cancer.
- Trial name
- NCT01644669
- Testing
- Intra-operative Radiation Therapy - IORT
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 1,200 people
- Sponsor
- Xoft, Inc.